Loading...
•
Dec 31, 2021
Akero Q4 2021 Earnings Report
Akero Therapeutics reported financial results for the fourth quarter and full year 2021.
Key Takeaways
Akero Therapeutics reported its fourth quarter and full year financial results for 2021, highlighting the continued advancement of its clinical trials for efruxifermin (EFX) in NASH patients and anticipation for Phase 2b HARMONY study results in Q3 of the year.
Akero remains on track to report Phase 2b HARMONY Study results in the third quarter of this year.
Akero is developing transformational treatments for patients with serious metabolic diseases.
EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study and the SYMMETRY study.
Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein.
Forward Guidance
The company's forward-looking statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...